Document:

Exhibit 10.1 Severance Agreement

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		
			Personal and Confidential
		

		
			 
		

		
			Delivered Via Email
		

		
			 
		

		
			 
		

		
			Timothy Stedman
		

		
			 
		

		
			Horgen, 10 April 2020
		

		
			 
		

		
			 
		

		
			Separation Agreement
		

		
			 
		

		
			Dear Tim,
		

		
			 
		

		
			We would like to summarize the mutually agreed to details concerning your resignation and separation from Trinseo Europe GmbH on 31 October 2020, unless otherwise adjusted as described below.
		

		
			 
		

		
			Termination Date, Release from Obligation to Work and Permission to Take New Employment
		

		
			We confirm that your employment with Trinseo Europe GmbH will terminate on 31 October 2020 (“End Employment Date”). Except as provide for herein, all your duties and rights according to your employment contract shall remain in force until this date. However, if you find a new employment position prior to 31 October 2020 you can, by giving us at least one week advance written notice, terminate your employment with the Company with effect as of this earlier new employment start date ("New Employment Start Date"). The amount of the Severance described below will not be impacted by your new employment.
		

		
			 
		

		
			Until your End Employment Date, you will serve as Special Advisor to the CEO and Executive Leadership Team.  All remaining and unused paid vacation that currently have accrued or may accrue in the future shall be taken before your End Employment Date.
		

		
			 
		

		
			The Company may require that you transition to a home office arrangement at any time after 3 July 2020 and give up your Horgen office.  The Company will provide you with at least 1 week notice of any such office transition.
		

		
			 
		

		
			Expenses
		

		
			All outstanding claims for expenses reasonably and properly incurred in the performance of your duties will be submitted and propertly reimbursed by the Company in ordinary course by 31 December 2020 assuming you will hand over any related receipts by 15 November 2020 the latest.
		

		
			 
		

		
			Severance
		

		
			Provided you provide the Company no later than on 6 November 2020 and no earlier than the End Employment Date with the attached general release that you have duly signed; you will be paid CHF 1,262,250 gross that is equal to one and one-half (1.5) multiplied by the sum of your current annual Base Salary and Target Bonus for the year of termination, paid in equal monthly installments for a period of eighteen (18) months following 31 October 2020. Should your employment for whatever reason be extended beyond the End Employment Date, this amount shall be reduced in kind by (i) one monthly installment, (ii) the employer's social security contributions and (iii) any additional costs that Trinseo might incur due to any such extension.
		

		
			

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		

		
			 
		

		
			Performance Award (PA) & Merit Increase
		

		
			You will be paid a pro-rata portion of your Target Bonus (i.e. Performance Award) for 2020 based on the End Employment Date (regardless of any New Employment Date) in accordance with the ordinary bonus payment cycle of the Company in March 2021. 
		

		
			 
		

		
			Long Term Incentive (LTI) Awards
		

		
			Any outstanding unvested LTI awards shall continue to vest under the 2014 Omnibus Incentive Plan through the End Employment Date.  Any outstanding unvested LTI awards that remain unvested as of the end date of employment will be handled under the 2014 Omnibus Incentive Plan and shall be forfeited. For the avoidance of doubt and without limiting the generality of the foregoing, all equity retention awards granted by Trinseo S.A. on September 14, 2018 are also forfeited as defined in the agreement that you have with Trinseo S.A. concerning that equity retention award. Any vested Stock Options from any LTI awards continue to be exercisable in accordance with the rules of the 2014 Omnibus Incentive Plan.
		

		
			 
		

		
			Outplacement Support
		

		
			Upon request, the Company will grant you outplacement support which will be provided through a defined consultant selected by the Company. There will be no payment in lieu.
		

		
			 
		

		
			Reference Letter
		

		
			At your request, Trinseo Europe GmbH will provide you with an interim reference letter within 20 days from your return of this agreement (including all required other documents) duly signed and with a final reference letter within 10 days from the End Employment Date.
		

		
			 
		

		
			Obligatory Accident Insurance
		

		
			On the 31th day after the day on which your entitlement to at least half of the salary ceases, the obligatory insurance for accidents during work time as well as accidents during leisure time expires. Unless you are insured against accidents with a new contract of employment within this 31 day period of time, you will be required to insure accident coverage from your personal sickness insurance fund. Another option would be to sign up for a voluntary accident insurance (Abredeversicherung) through our insurance SUVA. The necessary document can be downloaded from the homepage of SUVA.
		

		
			 
		

		
			Handover and Return of Employer’s Belongings
		

		
			You agree to return to us all business documents and other objects belonging or relating to Trinseo such as laptop (including the password), mobile phone including SIM card and any other objects which are in your possession without keeping copies (including but not limited to keys, badges, written or electronic or other documents, records, computers, discs and tapes, codes and data, mobile telephones, credit cards etc.) by the End Employment Date at the latest.
		

		
			 
		

		
			By this agreement, you acknowledge having resigned from all positions that you may hold with Trinseo S.A., including its subsidiaries; including as an Officer and executive leadership team member of Trinseo S.A. and a director of Trinseo Europe GmbH.  At Trinseo S.A.’s or its subsidiaries’ request, this shall also include any positions at Americas Styrenics LLC.  Furthermore, you agree to sign and return to us resignation letters for all positions as may be reasonably requested. 
		

		
			 
		

		
			

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		

		
			Without limiting the generality of the foreging, you agree to sign the resignation letter (separately provided to you) concerning your position as managing officer of Trinseo Europe GmbH and return it duly signed along with this agreement.
		

		
			 
		

		
			No Disparagement, NonCompetition & Confidentialty 
		

		
			The Company and you both undertake to use their reasonable endeavors to refrain from making any disparaging comments about each other in public communications (including, but not limited to, on websites and social media) or in private. As provided for under Swiss law, you are released from your noncompetition obligations once your employment term ends.  However, you acknowledge your ongoing duty of confidentiality to the Company remains after the End Employment Date.
		

		
			 
		

		
			Others & SEC 8K Filing
		

		
			You agree to sign a secrecy agreement and return it to the Human Resources department on the End Employment Date. 
		

		
			 
		

		
			Being on the New York Stock Exchange, Trinseo S.A. is subject to the United States Securities And Exchange Commission (“SEC”) laws and regulations.  Due to your status as a Named Executive Officer and your separation from the Company, this event and agreement are publically reportable on SEC Form 8-K.  Your separation will be reported on SEC Form 8-K no later than April 15, 2020.
		

		
			Tim, We believe above covers all of the discussed points and we wish you well in your future endeavors.  
		

		
			 
		

		
			
		

		
			

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		

		
			Should you agree with the contents of this agreement, please countersign this letter agreement in duplicate and return a signed original to us latest by the end of our business day 14 April 2020, otherwise this letter is deemed withdrawn, however, your End Employment Date shall remain as defined above. 
		

		
			 
		

		
			 
		

		
			 
		

		
			Best regards,
		

		
			Trinseo Europe GmbH
		

		
			 
		

		
			/s/ Alice Heezen
		

		
			 
		

		
			Alice Heezen
		

		
			SVP Human Resources 
		

		
			 
		

		
			 
		

		
			I have read this letter, understand it and agree to the terms and conditions set forth above:
		

		
			 
		

		
			Horgen, Switzerland
		

		
			 
		

		
			 
		

			
					
						Date: 13/4/2020

					
					
						Signature: 

					
					
						/s/ Timothy Stedman

				
	
					
						 

					
					
						 

					
					
						Timothy Stedman

				

		
			 
		

		
			
		

		
			

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		

		
			GENERAL RELEASE
		

		
			 
		

		
			I, Timothy Stedman, in consideration of and subject to the performance by Trinseo Europe GmbH (together with its affiliates, the “Company”), of its obligations under the Resignation & Separation Agreement, dated as of the date written below (the “Agreement”), do hereby release and forever discharge as of the date hereof the Company and its respective Affiliates and all present, former and future directors, officers, employees, successors and assigns of the Company and its Affiliates and direct or indirect owners (collectively, the “Released Parties”) to the extent provided below. The Released Parties are intended third-party beneficiaries of this General Release, and this General Release may be enforced by each of them in accordance with the terms hereof in respect of the rights granted to such Released Parties hereunder. Terms used herein but not otherwise defined shall have the meanings given to them in the Agreement.
		

		
			I understand that the severance, outplacement and other benefits paid or granted to me, and any other accomodations received, under the Agreement represent, in part, consideration for signing this General Release and are not salary, wages or benefits to which I was already entitled. I understand and agree that I will not receive certain of the payments and benefits specified in the Agreement unless I execute this General Release and do not revoke this General Release within the time period permitted hereafter. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.
		

		
			Except for the payments provided for in the Agreement, I knowingly and voluntarily (for myself, my heirs, executors, administrators and assigns) release and forever discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter‐claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys’ fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, suspected, or claimed against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or are connected with my employment with, or my separation or termination from, the Company (all of the foregoing collectively referred to herein as the “Claims”).
		

		
			I represent that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by the Agreement.
		

		
			I agree that this General Release does not waive or release any rights or claims that I may have which arise after the date I execute this General Release. I acknowledge and agree that my separation from employment with the Company in compliance with the terms of the Agreement shall not serve as the basis for any claim or action.
		

		
			I agree that I hereby waive all rights to sue or obtain equitable, remedial or punitive relief from any or all Released Parties of any kind whatsoever in respect of any Claim, including, without limitation, reinstatement, back pay, front pay, and any form of injunctive relief. Notwithstanding the above, I further acknowledge that I am not waiving and am not being required to waive any right that cannot be waived under law, including the right to file an administrative charge or participate in an administrative investigation or proceeding; provided, however, that I disclaim and waive any right to share or participate in any monetary award resulting from the prosecution of such charge or investigation or proceeding. Additionally, I am not waiving any right to the benefits or claims provided for in the Agreement.
		

		
			

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

		

		
			In signing this General Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any state or local statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential and material term of this General Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a Claim seeking damages against the Company, or in the event I should seek to recover against the Company in any Claim brought by a governmental agency on my behalf, this General Release shall serve as a complete defense to such Claims to the maximum extent permitted by law. I further agree that I am not aware of any pending Claim as of the execution of this General Release.
		

		
			I agree that neither this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any time to be an admission by the Company, any Released Party or myself of any improper or unlawful conduct.
		

		
			I agree that if I violate this General Release by suing the Company or the other Released Parties, I will pay all costs and expenses of defending against the suit incurred by the Released Parties, including reasonable attorneys’ fees.
		

		
			I agree that this General Release and the Agreement are confidential and agree not to disclose any information regarding the terms of this General Release or the Agreement, except to my immediate family and any tax, legal or other counsel I have consulted regarding the meaning or effect hereof or as required by law, and I will instruct each of the foregoing not to disclose the same to anyone. The Company agrees to disclose any such information only to any tax, legal or other counsel of the Company or as otherwise required by law.
		

		
			Any non‐disclosure provision in this General Release does not prohibit or restrict me (or my attorney) from responding to any inquiry about this General Release or its underlying facts and circumstances by the Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), any other self‐regulatory organization or any governmental entity.
		

		
			I hereby acknowledge that Sections 9, 11 through 15, 21 through 23 and 25 of the emplyoment agreement between Trinseo Europe GmbH and me dated August 7, 2015 shall survive my execution of this General Release. 
		

		
			I represent that I am not aware of any Claim by me other than the claims that are released by this General Release. I acknowledge that I may hereafter discover claims or facts in addition to or different than those which I now know or believe to exist with respect to the subject matter of the release set forth in this General Release and which, if known or suspected at the time of entering into this General Release, may have materially affected this General Release and my decision to enter into it. 
		

		
			Notwithstanding anything in this General Release to the contrary, this General Release shall not relinquish, diminish, or in any way affect any rights or claims arising out of any breach by the Company or by any Released Party of the Agreement after the date hereof.
		

		
			Whenever possible, each provision of this General Release shall be interpreted in, such manner as to be effective and valid under applicable law, but if any provision of this General Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any 

		 

		

			

		

		

			Trinseo Europe GmbH

		

		

			   Zugerstrasse 231   

		

		

			8810 Horgen, Switzerland

		

		

			 

		

other jurisdiction, but this General Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
		

		
			BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			I HAVE READ IT CAREFULLY;

			
	
			
				 2.
			

			
	
			
			I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS;

			
	
			
				 3.
			

			
	
			
			I VOLUNTARILY CONSENT TO EVERYTHING IN IT;

			
	
			
				 4.
			

			
	
			
			I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY; AND

			
	
			
				 5.
			

			
	
			
			I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.

		
			 
		

		
			 
		

		
			 
		

			
					
						Signature: 

					
					
						/s/ Timothy Stedman

					
					
						Date: 13/4/2020

				
	
					
						 

					
					
						Timothy StedmanExhibit
10.1

 

Collaboration
Agreement

 

This
Collaboration Agreement (“Agreement”) is entered into as of April 3, 2020 (the “Effective Date”) by and
between Tauriga Sciences Inc. (“Tauriga”) and Aegea Biotechnologies Inc. (“Aegea”) for the purpose of
together developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity
(the “SARS-Col 2 Test”).

 

Whereas,
the parties believe that the benefits of the SARS-CoV-2 Test are as follows: A Rapid SARS-CoV-2 test with unprecedented sensitivity
and specificity will eliminate false negatives and false positives and has the ability to detect and measure viral shed, even
in patients who are asymptomatic. This will directly help minimize and contain disease spread throughout the global community
as the world (global economy) attempts to return to normal functioning over the next 6-18 months. Moreover, this SARS-CoV-2 test
would use Aegea’s patented technologies, including Selector Technology, to take coronavirus testing to the next level by
differentiating different strains of SARS-CoV-2. The test would be adaptable to additional SARS-CoV-2 strain types as necessary
and as the virus mutates. It also could rapidly be customized to provide similarly sensitive and specific assays for other viruses,
current or future.

 

AND
WHEREAS, the Corporate Website for each party are as follows:

 

Tauriga Sciences Inc. (www.tauriea.com) & (www.taiirigum.com)

 

Aegea Biotechnologies, Inc. (httns://www.aeeeabiotcch.com)

 

NOW.
THEREFORE, for good and valuable consideration, the receipt and adequacy of which hereby acknowledged, the Parties agree as follows’

 

		A.	Tauriga
                                         General Obligations to Aegea:

 

Tauriga
has an ATM-Like Facility of $5,000,000 ELOC for a 3-year duration beginning on March 16, 2020 (the “ATM Facility”)
and will raise funding from this ATM Facility for the purposes set forth in this Agreement.

 

For
purposes of this Agreement, “Net Proceeds” refers to the amount of funds Tauriga nets after its commissions and fees
are deducted from each ELOC Tranche (estimated at approximately 88% of gross proceeds, which is deemed as Net proceeds)

 

1) Seventy
percent (70%) of the Net Proceeds from the sale of the initial 10,000,000 shares of stock of Tauriga using the ATM Facility will
be transferred to Aegea and invested in Aegea and used to purchase common stock of Aegea, pursuant to the terms of the Stock Purchase
Agreement in the form attached hereto as Exhibit A (the “Stock Purchase Agreement”) at a purchase price Four
Dollars ($4.00) per share.

 

 2) After the sale of the initial 10,000,000 shares of Tauriga using the ATM Facility, Twenty percent (20%) of all subsequent Net Proceeds generated using the ATM Facility shall be transferred by wire transfer to Aegea for the purchase of additional shares of common stock of Aegea pursuant to the terms of the Stock Purchase Agreement.

 

    	 	 	 

    	 

    

 

3) Tauriga’s investment bank (Tangiers Global, LLC) will provide statements of all using the ATM Facility directly
to Aegea’s Chief Business Officer (Dr. Stella Sung) at the same time it provides the statements to Tauriga’s CEO (Mr.
Seth Shaw). Tauriga will wire to Aegea agreed upon amount of all such Net Proceeds (70% of the initial 10,000,000 shares and thereafter)
within one business day of Tauriga’s receipt of any such proceeds from such sales of stock of Tauriga.

 

4) This
Agreement will commence on the Effective Date and will continue indefinitely, unless amended or terminated by mutual written agreement
by both parties.

 

5) Tauriga
shall make available to Aegea, its entire rolodex and infrastructure, for the benefit of the Co-Development of the SARS-CoV-2
Test.

 

 6) Tauriga shall issue to Aegea 5,000,000 shares Tauriga common stock within 90 days of the Effective Date of this Agreement (Rule 144 Date shall begin from the date of execution of Agreement).

 

		B.	Aegea
                                         General Obligations to Tauriga:

 

1) The
common stock in Aegea shall be acquired by Tauriga, as each Tranche of Cash (generated by Tauriga via the $5,000,000 ELOC is completed).
Aegea agrees to sell the common stock to Tauriga at a price of $4.00 per share (which corresponds to a current pre-money valuation
of Aegea of $25 million) for each Tranche of Cash, up to the first $2 million of Tauriga investment in Aegea. The Aegea agreed
upon valuation will be re-negotiated by the parties after the first $2 million of Tauriga investment is received by Aegea.

 

2) On
an annual basis, Aegea shall provide Tauriga with a pro rata share of Aegea’s net profits from all sales of the SARS-Cov-2
Test (such pro-rata share shall be based upon Tauriga’s equity ownership in Aegea at the end of each such year). Tauriga’s
pro rata share of net profits from SARS-CoV-2 Tests will be wired within 60 days from the end of the relevant calendar year.

 

3) Best
Efforts Basis - Aegea shall help Tauriga apply Aegea’s intellectual property (invented by Dr. Lyle Arnold) and know how
to improve the bioavailability of Tauriga’s CBD products within the framework of Tauriga’s existing core business(es).

 

4) Aegea
will draft the (joint) press release announcing the Tauriga/Aegea collaboration for developing the next generation coronavirus
test. Tauriga will have the opportunity to review and approve the press release prior to distribution. The announcement will highlight
the patented science and explain how the technology can elevate coronavirus testing to a new level of sensitivity and specificity,
and the potential global health benefit. All future press releases and public communications that mention the Tauriga/Aegea coronavirus
collaboration will also be drafted by Aegea (to ensure scientific accuracy), and Tauriga will have the opportunity to review and
approve such press releases prior to distribution.

 

    	 	- 2 -	 

    	 

    

 

		C.	Intellectual
                                         Property. Each party acknowledges and agrees that each party is the sole and exclusive
                                         owner of their respective Intellectual Property Rights (“IP Rights”) existing
                                         as at the Effective Date (“Pre-existing IP Rights”) in addition to any modification,
                                         derivative or improvement in any Pre-existing IP Rights.Other than specifically provided
                                         in this Agreement, neither party shall transfer to the other party any right to any of
                                         a party’s Pre-Existing IP Rights.
	 	 	 
		D.	Additional
                                         Provisions. The parties agree that the Additional Provisions attached hereto as
                                         Exhibit B shall be incorporated into this Agreement.

 

IN
WITNESS WHEREOF, each party has caused this Collaboration Agreement to be executed and effective as of the Effective Date first
written above.

 

	Aegea
    Biosciences Inc,	 	Tauriga
    Sciences, Inc
	 	 	 	 
	By:	 	 	By:	
	 	President	 	 	Seth
    Shaw, CEO
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	 	Board
    Member
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	 	Board
    Member

 

    	 	- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]